[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mri-guided-adaptive-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mri-guided-adaptive-radiotherapy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100621015","mrinrt-swansea-university-and-swwcc-collaboration-study-100621015",false,"NCT07365124","MRinRT: Swansea University and SWWCC Collaboration Study.","Developing and Optimising the Use of Magnetic Resonance Imaging and Spectroscopy in Radiotherapy (MRinRT) Pathways: Investigating Avenues to Improve Outcomes for Patients and the Assessment of Treatment Response.","MRinRT","Inclusion Criteria for health volunteers:\n\n* Free from medical conditions that could confound imaging or study results\n* Eligible for MRI\n\nInclusion Criteria for patients:\n\n* Confirmed diagnosis of invasive carcinoma at the relevant tumour\u002Ftarget sites listed in this protocol\n* Scheduled to receive radiotherapy to the target site\n* ECOG performance status of 0-2\n* Eligible for MRI (determined through MRI safety screening)\n\nExclusion Criteria:\n\n* Presence of medical conditions that may interfere with study outcomes or data interpretation\n* Use of regular medications that could affect imaging results or safety\n* Any contraindications to MRI scanning, including but not limited to claustrophobia, reduced thermal regulatory capabilities, MR Unsafe implants and foreign bodies.",true,"ALL","18 Years",{"count":21,"type":22},165,"ESTIMATED","OBSERVATIONAL","The aim of this study is to learn whether using MRI (magnetic resonance imaging) scans to plan radiotherapy is better than using CT (computed tomography) scans alone. The main questions it aims to answer is:\n\n* Can MRI scan images be adjusted to make the tumour and normal tissues easier to see?\n* Does adding MRI to a radiotherapy planning CT make the radiotherapy plan more precise?\n* Can MRI be used to adjust a radiotherapy plan during a course of treatment to make it more precise, and might that reduce the side effects?\n* Are there particular MRI scans that can predict how a tumour will respond to radiotherapy or how likely the patient is to have side effects?\n\nThis study will assess current MRI scanning procedures and ensure these are adjusted to best suit radiotherapy planning. It will also provide pilot data evaluating:\n\n1. MRI-adapted radiotherapy Usually, radiotherapy plans are based on a pre-treatment planning CT scan. Unless an issue is detected the patient would complete their whole course of radiotherapy on this plan. This does not account for changes in position\u002Fsize\u002Fshape of the tumour that occur over the whole treatment course. Clinicians therefore increase the size of the tumour\u002Ftarget to account for these uncertainties, which can increase side effects. This study will assess the potential to reduce side effects from radiotherapy by using repeat MRI scans and replanning during the treatment course (MRI-adaptive radiotherapy).\n2. Imaging biomarkers MRI sequences can be used to predict response to radiotherapy or chance of developing side effects. This study will identify potential MRI sequences that may be used as imaging biomarkers, to guide the development of future clinical trials.\n\nThe study will be undertaken at SBUHB, lasting 4 years, and involving ≤15 healthy volunteers and ≤150 patients.",[26,27,28,29,30,31,32,33,34,35,36],"Carcinoma","Glioblastoma","Radiotherapy","MRI","MRI-guided Adaptive Radiotherapy","MRI Scanner Configuration","MRI Image Enhancement","Oesophageal Carcinoma","Pancreas Carcinoma","Gastric Cancer","Brain (Nervous System) Cancers",[29,28,38,39],"MRI adaptive radiotherapy","MRI Imaging Biomarker","NOT_YET_RECRUITING","2026-04-29",{"date":43,"type":44},"2026-04-30","ACTUAL",{"date":46,"type":22},"2026-05",{"date":48,"type":22},"2032-01",{"name":50,"class":51},"Swansea Bay University Health Board","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":52},"100560883","phase-2-elimination-of-ptv-margins-based-on-mri-guided-adaptive-stereotactic-radiotherapy-for-non-small-cell-lung-cancer-with-brain-metastasis-100560883","NCT06582940","Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis","Inclusion Criteria:\n\n* Aged 18-75 years\n* Histologically or cytologically confirmed non-small cell lung cancer\n* 1-10 metastases on contrast-enhanced MRI\n* Radiotherapy for extracranial lesions is permitted\n* Tyrosine kinase inhibitors (TKI) are permitted in patients with progression of\n* intracranial metastases during previous TKI therapy\n* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Normal function of organs and bone marrow within 14 days: Total bilirubin 1.5 times or less the upper limits of normal (ULN); AST and ALT 1.5 times or less the ULN; absolute neutrophil count≥ 500 cells\u002Fmm3; creatinine clearance rate(CCR) ≥45 mL\u002Fmin; Platelet count≥50,000 cells\u002Fmm3; international normalized ratio(INR) ≤1.5#Prothrombin Time (PT)≤ 1.5 × ULN\n* Informed-consent\n\nExclusion Criteria:\n\n* Small cell carcinoma of lung\n* Intracranial metastases needed surgical decompression\n* Patients with contraindications for MRI\n* Previous radiotherapy or excision for intracranial metastases\n* Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (New York class II or above), active cerebrovascular disease or cardiovascular disease occurred within 6 months\n* Uncontrolled hypertension (systolic \\> 150mmHg and\u002For diastolic \\> 100mmHg)\n* Major surgery within 28 days or minor surgery or needle biopsy within 48 hours\n* Urine protein 3-4+, or 24h urine protein quantitative \\>1g\n* Severe uncontrolled disease\n* Uncontrollable seizure or psychotic patients without self-control ability\n* Women in pregnancy, lactation period\n* Other not suitable conditions determined by the investigators","75 Years",{"count":61,"type":22},168,"INTERVENTIONAL",[64],"PHASE2","This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain metastasis.",[30,67,68],"Non-small Cell Lung Cancer","Brain Metastasis",[70,71,72],"MRI-guided radiotherapy","lung cancer","brain metastasis","RECRUITING","2025-11-14",{"date":76,"type":44},"2025-11-17",{"date":78,"type":44},"2024-03-01",{"date":80,"type":22},"2026-03-01",{"name":82,"class":51},"Sun Yat-sen University"]